MOUD Buprenorphine Sublocade denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for moud buprenorphine sublocade are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Sublocade — and How to Challenge It

A step-therapy denial for Sublocade means UnitedHealthcare requires that a patient try and fail (or document a contraindication to) one or more preferred-tier buprenorphine products — typically sublingual films or tablets — before approving the extended-release injectable formulation. This "fail-first" requirement is among the most common barriers to MOUD access and among the most commonly overturned on appeal, particularly when the clinical record already documents the relevant step-therapy history.

## Why Step-Therapy Denials Are Appealable

Many states have enacted step-therapy reform laws that require insurers to grant an exception when the patient has already tried the required prior step, when the required step is contraindicated, or when requiring the step would cause clinically significant harm. Even in states without specific step-therapy statutes, ERISA and ACA appeal rights apply. Additionally, MHPAEA prohibits more burdensome step-therapy requirements for substance use disorder treatment than for analogous medical conditions — if UHC does not require comparable step-therapy for other chronic-disease maintenance medications, that asymmetry is a parity argument.

## Your Federal Appeal Rights

• Step-therapy exception / prior authorization override: Before or alongside a formal appeal, request a step-therapy exception. The prescriber documents that the required prior step has already been tried, is contraindicated, or is clinically inappropriate.
• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on the denial letter.
• External review: After internal exhaustion, request independent external review under ACA §2719 — typically within four months of the internal denial notice.
• Expedited review: Available if the step-therapy requirement creates an urgent clinical risk.

## Concrete Appeal Steps

1. Obtain the denial letter and identify precisely which prior-step drug(s) UHC requires. 2. Review the clinical record to determine whether the patient has already tried any of the required prior steps. If so, that prior history — with dates and outcomes — is the core of your appeal. 3. Pull UHC's published step-therapy criteria for Sublocade. 4. Have the prescriber draft a letter documenting prior-step history and/or clinical rationale for bypassing the step. 5. Check your state's step-therapy reform law — many states require exception approval within a defined timeframe. 6. File the appeal with the documentation package below.

## Documentation to Gather

• Prior-step trial history: Dates, specific product names, adherence records, and documented outcomes for each sublingual buprenorphine product tried. If the patient had adherence problems, diversion concerns, or inadequate response, document each specifically.
• Contraindication or clinical bypass rationale: If the required step cannot be safely tried, the prescriber documents why — referencing clinical judgment, not specific drug-interaction databases (which the prescriber will consult but should be documented in their letter).
• Diagnosis confirmation: DSM-5 moderate-to-severe OUD.
• Prescriber medical-necessity letter: Directly addressing each required prior step, with chart-based outcomes, and explaining the clinical rationale for the injectable formulation.
• Criteria-mapping table: Each UHC step-therapy requirement in one column; the chart evidence or prescriber attestation satisfying it in the other.

## Criteria-Mapping Structure

Step-therapy tables typically have one row per required prior step. For each row: (1) the required drug, (2) date(s) tried or basis for exception, (3) outcome or contraindication documented in chart. A complete table with no blank rows is the single most important factor in a successful step-therapy appeal.